PRESS RELEASE

19 November 2026 08:00:00 CET

Invitation to Saniona Q3 investor call on 26 November 2026

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, will host a Q3 investor call on 26 November 2026, at 15.00 CET

At the call Management will be presenting results and a company update. At the end of the presentation there will be a Q&A session, where participants can ask online questions.

Access to the event can be obtained through the following link:

Live Q: Saniona - Redeye

REPLAY access
Webcast replay will be available at **www.saniona.com** and at **www.redeye.se**

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company's internal pipeline includes SAN2668 for pediatric epilepsy syndromes and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico, and Argentina. Saniona's ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, Cephagenix and AstronauTx, which holds worldwide rights to ATX0926. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market.
For more information, visit **www.saniona.com**.

For more information, please contact
Johnny Stilou, CFO, +45 21227227; **johnny.stilou@saniona.com**

Attachments
Invitation to Saniona Q3 investor call on 26 November 2026